Citigroup Inc Werewolf Therapeutics, Inc. Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 8,661 shares of HOWL stock, worth $8,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,661

Previous 321 2598.13%

Holding current value

$8,141

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$1.05 - $2.19 $8,757 - $18,264	8,340 Added 2598.13%	8,661 $17,000
Q2 2025 Aug 11, 2025	SELL	$0.63 - $1.42 $13,599 - $30,652	-21,586 Reduced 98.53%	321 $0
Q1 2025 May 12, 2025	SELL	$0.97 - $1.68 $1,767 - $3,060	-1,822 Reduced 7.68%	21,907 $21,000
Q4 2024 Feb 12, 2025	BUY	$1.48 - $3.63 $1,062 - $2,606	718 Added 3.12%	23,729 $35,000
Q3 2024 Nov 12, 2024	BUY	$1.71 - $2.95 $27,736 - $47,849	16,220 Added 238.85%	23,011 $48,000
Q2 2024 Aug 12, 2024	SELL	$2.34 - $6.75 $151,550 - $437,163	-64,765 Reduced 90.51%	6,791 $16,000
Q1 2024 May 10, 2024	BUY	$3.92 - $7.91 $280,499 - $566,007	71,556 New	71,556 $463,000
Q4 2022 Feb 09, 2023	SELL	$1.53 - $4.73 $540 - $1,669	-353 Reduced 82.67%	74 $0
Q3 2022 Nov 10, 2022	SELL	$4.14 - $7.42 $1,279 - $2,292	-309 Reduced 41.98%	427 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.43 - $5.98 $6,674 - $11,637	-1,946 Reduced 72.56%	736 $3,000
Q1 2022 May 12, 2022	SELL	$3.71 - $12.22 $19,432 - $64,008	-5,238 Reduced 66.14%	2,682 $12,000
Q4 2021 Feb 10, 2022	BUY	$11.48 - $17.65 $80,968 - $124,485	7,053 Added 813.49%	7,920 $94,000
Q3 2021 Nov 10, 2021	BUY	$13.89 - $20.31 $12,042 - $17,608	867 New	867 $15,000

Others Institutions Holding HOWL

# of Institutions

Shares Held

23.4M

Call Options Held

Put Options Held

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $27.8M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account